A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis

You may be eligible if

• Patients undergoing chronic haemodialysis via an arteriovenous graft
• Arteriovenous graft in place for at least 3 months
• Duration of haemodialysis of at least 3 months, with 3 full dialysis sessions per week with a duration between 2 and 5 hours per session
• Women patients must be either postmenopausal for more than 1 year or, if of childbearing age, must use adequate contraception
• Women patients must have a negative serum pregnancy test within one week of randomisation
• Able to provide written informed consent prior to study participation